Drug: Reclast
Generic: Zoledronic acid injection
The company: Novartis ($NVS)
Patent expiration date: March 2, 2013
Estimated Global Sales 2012: $612 million

The scoop: Swiss drugmaker Novartis is bracing itself for a tough few quarters. The company already experienced quite the slump in U.S. sales of its hypertension, heart failure and heart attack drug Diovan since the product's patent expired in September. And 2013 brings more losses; cancer treatment Zometa and osteoporosis treatment Reclast/Aclasta will lose patent protection. Reclast will garner $612 million in estimated sales this year. Novartis is doing what it can to protect its product. In July, the company sued Sun Pharmaceuticals to block it from selling generic forms of Zometa and Reclast. We'll see how that pans out in court.

For more:
Gilenya, Afinitor among bright spots in flat Novartis quarter
FDA panel wants bone drugs' labeling changed, but how?


Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.